Partnership for Applied Research in Fracture Prevention Programs for the Elderly (OPTI-FRAC)
26. oktober 2018 oppdatert av: Isabelle Gaboury, Université de Sherbrooke
During their lifetime, approximately 50% of Canadian women and 30% of Canadian men will experience at least one fracture due to bone fragility (FF).
Evidence is growing regarding prevention programs' effectiveness to prevent falls, but prevention of fractures through fall prevention programs has enjoyed limited success.
Falls prevention programs and post-fracture screening programs leading to pharmacological treatment are very different strategies, with a shared ultimate goal.
Coordination between those who repair fractures and those who manage the patient to prevent the next fracture is critical.
The overarching aim of this proposal is to generate evidence-based knowledge about the effectiveness and cost-effectiveness of an integrated FF prevention program, as well as a portrait of the barriers and facilitating factors for such programs.
More specifically, the objectives are: 1) to combine existing fall prevention and post-fracture management programs in the province of Quebec into integrated FF prevention programs; 2) to compare the performance of these integrated programs to control sites, using a pragmatic study design; 3) to identify barriers as well as factors that improve effectiveness across different implementation milieu; and 4) to develop and engage in active knowledge transfer activities in Quebec regions where integrated FF prevention programs are neither adequately nor successfully implemented.
Drawing upon the literature on integrated healthcare, fall and fracture prevention, we hypothesize that an integrated FF program can reduce the risk of a subsequent fracture by at least 30% in the population of interest.
The proposed team is poised to develop new interdisciplinary collaborations among healthcare practitioners and decision makers involved in the prevention of FFs.
The program is built upon existing healthcare and structures and programs and in turn, will truly measure the effectiveness of an integrated FF prevention program.
The results will ultimately lead to improvements in the existing knowledge base, address policy-relevant and health systems problems, and assist in the design and implementation of FFs prevention programs.
Studieoversikt
Status
Ukjent
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
631
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Quebec
-
Amos, Quebec, Canada, J9T 2S2
- Centre hospitalier Hôtel-Dieu d'Amos
-
Chandler, Quebec, Canada, G0C 1K0
- CSSS du Roché Percé (Centre hospitalier de Chandler)
-
Gatineau, Quebec, Canada, J8Y 1W7
- Hôpital de Hull
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Hôpital Charles LeMoyne
-
Montreal, Quebec, Canada, H1T 2M4
- Hopital Maisonneuve-Rosemont
-
Montreal, Quebec, Canada, H4J 1C5
- Hôpital Sacré-Coeur de Montréal
-
Montreal, Quebec, Canada, H2E1S6
- Hôpital Jean-Talon
-
Saint-Charles-Borromée, Quebec, Canada, J6E 6J2
- Centre hospitalier régional de Lanaudière
-
Sherbrooke, Quebec, Canada, J1H5N4
- Centre Hospitalier Universitaire de Sherbrooke
-
St-Jérôme, Quebec, Canada, J7Z 5T3
- CSSS de St-Jérôme (Hôpital régional de St-Jérôme)
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
50 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- 50 years of age and over
- must have a primary care physician
- must be able to follow simple instructions
- must have sustained a fragility fracture within three months of the recruitment date.
Exclusion Criteria:
- severe kidney insufficiency (grade 4 or 5)
- advanced stage of cancer
- fracture to sites not commonly associated with osteoporosis such as toe, finger, hand, foot, ankle, patella, head, and cervical spine.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Ingen inngripen: Kontrollgruppe
|
|
|
Eksperimentell: Integrated program
Participants will be involved in an integrated interorganisational fragility fracture prevention program, which combines both post-fracture management as well as fall prevention strategies.
The intervention will last up to 18 months.
|
Each participant's primary care physician will receive written information containing a presumed osteoporosis diagnosis, investigations to be performed, correct interpretation of any bone densitometry results in the context of a fragility fracture, and treatment options.
The study coordinator will be responsible for orienting the participant to an appropriate local fall prevention program.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Incidence of secondary fragility fracture
Tidsramme: 18 months post recruitment
|
18 months post recruitment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Initiation of osteoporosis treatment by the primary care physician
Tidsramme: At 6, 12, 18, and 60 months post recruitment
|
Osteoporosis treatment includes bisphosphonates or other effective osteoporosis drugs.
|
At 6, 12, 18, and 60 months post recruitment
|
|
Compliance with osteoporosis treatment.
Tidsramme: At 6, 12, 18, and 60 months post recruitment
|
The data collected from the participant will be validated with the participant's pharmacist through the medication possession ratio.
The medication possession ratio is measured from the first to the last prescription, with the denominator being the duration from index to the exhaustion of the last prescription and the numerator being the days supplied over that period from first to last prescription and the numerator being the total number of days in the interval.
|
At 6, 12, 18, and 60 months post recruitment
|
|
Time to first fall event
Tidsramme: Within the first 18 months post recruitment
|
Within the first 18 months post recruitment
|
|
|
Incidence of secondary fragility fractures.
Tidsramme: At 24, 36, 48 and 60 months post recruitment
|
At 24, 36, 48 and 60 months post recruitment
|
|
|
Number of clinically significant fall events.
Tidsramme: At 18, 24, 36, 48 and 60 months post recruitment
|
At 18, 24, 36, 48 and 60 months post recruitment
|
|
|
Fall-related hospitalizations
Tidsramme: At 18, 24, 36, 48 and 60 months post recruitment
|
Fall-related hospitalizations will be recorded in the participant diary and at each telephone follow-up, and validated with the participant's hospital records.
|
At 18, 24, 36, 48 and 60 months post recruitment
|
|
Fragility fracture-related death
Tidsramme: At 18, 24, 36, 48 and 60 months post recruitment
|
Fragility fracture-related death will be confirmed from a provincial administrative database (Regie de l'assurance maladie du Quebec - RAMQ).
|
At 18, 24, 36, 48 and 60 months post recruitment
|
|
Participants' quality of life
Tidsramme: At 18, 24, 36, 48 and 60 months post recruitment
|
Euro-QOL
|
At 18, 24, 36, 48 and 60 months post recruitment
|
|
Practice of physical activities
Tidsramme: At 6, 12, 18, 24, 36, 48 and 60 months post recruitment
|
CHAMPS
|
At 6, 12, 18, 24, 36, 48 and 60 months post recruitment
|
|
Fragility fracture-related costs
Tidsramme: At 18 and 60 months post recruitment
|
Medical costs from the participant's hospital record include: medical assessment, prescription and non-prescription drugs; and resource use related to the management of the fragility fracture and/or long-term complications, including hospitalization.
As well, lost days of work, annual income (if the participant is in the labour force), travel to the hospital and/or rehabilitation facilities, parking, and out-of-pocket expenses for drugs and rehabilitation devices (e.g.
splint) will be compiled.
Protocol-driven costs will be excluded, with the exception of the costs related to the participants' fall prevention program.
|
At 18 and 60 months post recruitment
|
|
Admission to a long-term care facility
Tidsramme: At 18, 24, 36, 48 and 60 months post recruitment
|
At 18, 24, 36, 48 and 60 months post recruitment
|
|
|
Participants' perceptions of care integration
Tidsramme: At 12 months post intervention
|
All participants' perceptions of care integration will be captured 12 months after the beginning of the intervention period, or following an early withdrawal from the study.
|
At 12 months post intervention
|
|
Intervention participant's satisfaction with the fragility fracture prevention program
Tidsramme: At 12 months post intervention
|
At 12 months post intervention
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Isabelle Gaboury, PhD, Université de Sherbrooke
- Hovedetterforsker: Hélène Corriveau, PhD pht, Université de Sherbrooke
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. januar 2013
Primær fullføring (Faktiske)
1. november 2016
Studiet fullført (Forventet)
1. juni 2019
Datoer for studieregistrering
Først innsendt
5. desember 2012
Først innsendt som oppfylte QC-kriteriene
5. desember 2012
Først lagt ut (Anslag)
7. desember 2012
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
29. oktober 2018
Siste oppdatering sendt inn som oppfylte QC-kriteriene
26. oktober 2018
Sist bekreftet
1. oktober 2018
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CIHR grant # 267395
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .